The Lancet publishes commentary on AMR Benchmark
Thursday, 12 October 2017
CAN THE ANTIMICROBIAL RESISTANCE BENCHMARK BLAZE A NEW TRAIL?
A new Commentary published today in The Lancet discusses the potential of the new Antimicrobial Resistance Benchmark to stimulate pharmaceutical companies to limit antimicrobial resistance. The Commentary has been co-authored by Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, and Marc Mendelson, Professor of Infectious Diseases and Head of the Division of Infectious Diseases & HIV Medicine, Groote Schuur Hospital, University of Cape Town, South Africa.
The Antimicrobial Resistance Benchmark is the first independently developed framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance (AMR). It was developed through consultation with stakeholders and experts working in AMR to build consensus on the priorities for pharmaceutical companies in AMR. To The Lancet >>>
About the Access to Medicine Index
The Access to Medicine Index analyses 20 of the world’s largest research-based pharmaceutical companies with products for high-burden diseases in low- and middle-income countries. The Index ranks these companies according to their efforts to improve access to medicine in seven areas of corporate behaviour, including pricing, patents, ethical behaviour and donations. It covers 107 low- and middle-income countries and 50 high-burden diseases, and examines eight types of products, from medicines to vaccines to diagnostics. The Index identifies best practices, highlights where progress is being made, and uncovers where critical action is still required. In this way, the Index provides both an incentive and a guide for pharmaceutical companies to do more to improve access to medicine. It is published every two years by the Access to Medicine Foundation, an independent non-profit organisation.
About the Access to Medicine Foundation
The Access to Medicine Foundation is an independent, nonprofit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine. The Foundation is funded by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs and the UK Department for International Development. For ten years, the Foundation has been building consensus on the role for the pharmaceutical industry in improving access to medicine and vaccines. It published its first benchmark of industry activity in this area in 2008, in the first Access to Medicine Index. The fifth Access to Medicine Index was published in November 2016. In 2017, the Foundation will publish the first Access to Vaccines Index, funded by the Dutch National Postcode Lottery, and the first AntiMicrobial Benchmark, funded by the UK and Dutch governments.